Your browser doesn't support javascript.
loading
Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP).
Butzkueven, Helmut; Kappos, Ludwig; Wiendl, Heinz; Trojano, Maria; Spelman, Tim; Chang, Ih; Kasliwal, Rachna; Jaitly, Seema; Campbell, Nolan; Ho, Pei-Ran; Licata, Stephanie.
Afiliación
  • Butzkueven H; Department of Neuroscience, Central Clinical School, Alfred Campus, Monash University, Melbourne, Victoria, Australia.
  • Kappos L; Neurologic Clinic and Policlinic, Departments of Medicine, Clinical Research, Biomedicine and Biomedical Engineering, University Hospital and University of Basel, Basel, Switzerland.
  • Wiendl H; Department of Neurology, University of Münster, Münster, Germany.
  • Trojano M; Department of Basic Medical Science, Neuroscience and Sense Organs, University of Bari, Bari, Italy.
  • Spelman T; Department of Medicine and Melbourne Brain Centre at the Royal Melbourne Hospital, University of Melbourne, Melbourne, Victoria, Australia.
  • Chang I; Department of Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden.
  • Kasliwal R; Biostatistics, Biogen, Cambridge, Massachusetts, USA.
  • Jaitly S; Safety and Benefit Risk, Biogen, Cambridge, Massachusetts, USA (at the time of these analyses).
  • Campbell N; Safety and Benefit Risk, Biogen, Cambridge, Massachusetts, USA (at the time of these analyses).
  • Ho PR; Global Medical, Biogen, Cambridge, Massachusetts, USA.
  • Licata S; Global Medical, Biogen, Cambridge, Massachusetts, USA.
J Neurol Neurosurg Psychiatry ; 91(6): 660-668, 2020 06.
Article en En | MEDLINE | ID: mdl-32234967
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Esclerosis Múltiple Recurrente-Remitente / Natalizumab / Factores Inmunológicos Tipo de estudio: Evaluation_studies / Observational_studies / Prognostic_studies Idioma: En Revista: J Neurol Neurosurg Psychiatry Año: 2020 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Esclerosis Múltiple Recurrente-Remitente / Natalizumab / Factores Inmunológicos Tipo de estudio: Evaluation_studies / Observational_studies / Prognostic_studies Idioma: En Revista: J Neurol Neurosurg Psychiatry Año: 2020 Tipo del documento: Article